OncoMatch/Clinical Trials/NCT05725200
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Is NCT05725200 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for metastatic colorectal cancer.
Treatment: Alectinib · Cetuximab · Crizotinib · Dasatinib · Everolimus · Encorafenib · Gemcitabine · Idelalisib · Larotrectinib · Methotrexate · Palbociclib · Panobinostat · Pembrolizumab · Petrozumab · Trastuzumab · Talazoparib · Venetoclax — The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: RAS wild-type
Patients with the gene RAS wild-type tumors should have received or have been offered and refused prior treatment with antibodies against epidermal growth factor receptor (EGFR)...
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — metastatic
Has received at least two lines of SOC chemotherapy for mCRC
Must have received: EGFR-targeted therapy — metastatic
Patients with the gene RAS wild-type tumors should have received or have been offered and refused prior treatment with antibodies against epidermal growth factor receptor (EGFR) (e.g. in combination with prior lines of chemotherapy) unless it was contraindicated due to underlying conditions or the tumor contains molecular alterations suggested to provide primary resistance to EGFR-targeted therapy.
Cannot have received: selected study drug
Has received previous treatment with the selected study drug for the same malignancy.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5/nL; Hemoglobin > 10 g/dL; Platelets > 100/nL
Kidney function
Calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Liver function
Total bilirubin < 1.5 x institutional upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 x ULN (or < 5 x ULN in patients with known hepatic metastases)
Cardiac function
Left ventricular ejection fraction (LVEF) known to be < 40% [excluded]; preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure [excluded]; stroke (including TIA) or acute myocardial infarction within 6 months before first dose of study treatment [excluded]
Has acceptable organ function as defined below... Absolute neutrophil count ≥ 1.5/nL (nL = nano Litre); Hemoglobin > 10 g/dL; Platelets > 100/nL; Total bilirubin < 1.5 x institutional upper limit of normal (ULN); AST (SGOT) and ALT(SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases); Calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify